Core C - Functional Genomics and Computational Biology Core

核心 C - 功能基因组学和计算生物学核心

基本信息

  • 批准号:
    10239108
  • 负责人:
  • 金额:
    $ 21.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-05-15 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

CORE SUMMARY The overall goal of this PPG application is to compare and contrast the mechanisms by which the inhibitory receptors PD1 and LAG3 operate on T cells in the context of tolerance and autoimmunity, cancer, and chronic infection. One major approach to be used throughout the studies is the application of genome-wide transcriptional profiling. The purpose of the Functional Genomics and Computational Biology Core (Core C) is to provide essential and centralized sequencing-based genomics services for all three Projects in this Program. In addition, this Core will operate provide the service of a retroviral (RV)-enforced expression and knockdown platform that can directly test in vivo individual genes and pathways identified from computational analyses. Thus, Core C will provide integrated bioinformatic and computational analytical platforms and data integration services coupled to downstream RV-enforced expression and knockdown as well as in vivo CRISPR/Cas9-focused genetic screening. The Aims are: AIM 1: To provide initial data hosting, normalization, preprocessing, and analysis as well as perform cross-Project data integration and computational network modeling for bulk and single-cell transcriptomic and epigenetic datasets. Core C will (i) provide raw data QC, data cleaning, pre-processing, and generation of files for downstream analyses as well as operate a web portal interface for user exploration of the data; (ii) perform primary and secondary genomics data analyses; and (iii) perform network and integrated analyses including. The Core also will support and/or develop new analytical tools as technologies become available (as for scRNA-seq in the last cycle). AIM 2: To enable in vivo CRISPR/Cas9 screening and provide an RV-enforced expression and knowckdown platform for downstream in vivo interrogation of genes and pathways regulated by PD-1 and/or LAG3. Core C will aid in design of CRISPR screening libraries for in vivo CRISPR screening platforms by the Projects as well as downstream data analysis. Core C will also provide an in vivo retroviral platform to enforce expression or shRNA knock-down of high-priority GOIs. By its nature, Core C is highly interactive with other components of this PPG. Samples from Projects 1, 2, and 3 will enter Core C, which will analyze samples with input from the Projects and integrate results among the three Projects. Core C will interact heavily with Cores A, B, and D for administrative support and to identify gene targets for novel mouse strains and immunostaining analysis.
核心摘要 本PPG应用程序的总体目标是比较和对比抑制性药物的作用机制。 受体PD 1和LAG 3在耐受性和自身免疫、癌症和慢性炎症的背景下对T细胞起作用。 感染在整个研究中使用的一个主要方法是应用全基因组 转录谱分析功能基因组学和计算生物学核心(核心C)的目的是 为该计划中的所有三个项目提供必要的和集中的基于测序的基因组服务。 此外,该核心将提供逆转录病毒(RV)强制表达和敲低的服务。 该平台可以直接测试从计算分析中识别的体内个体基因和途径。因此,在本发明中, 核心C将提供集成的生物信息学和计算分析平台以及数据集成服务 与下游RV-强制表达和敲低以及体内CRISPR/Cas9-聚焦结合, 基因筛选目标是: 目标1:提供初始数据托管、规范化、预处理和分析,并执行 跨项目数据集成和计算网络建模,适用于批量和单电池 转录组和表观遗传数据集。核心C将(i)提供原始数据QC、数据清理、预处理, 和生成用于下游分析的文件,以及操作用于用户探索 数据;(ii)进行初级和二级基因组学数据分析;以及(iii)进行网络和集成 分析包括。随着技术的发展,核心还将支持和/或开发新的分析工具。 可用(与上一个循环中的scRNA-seq相同)。 目的2:为了能够进行体内CRISPR/Cas9筛选并提供RV-强制表达, 用于PD-1调控的基因和途径的下游体内询问的knockdown平台 和/或LAG 3。核心C将帮助设计用于体内CRISPR筛选平台的CRISPR筛选文库 以及下游数据分析。Core C还将提供一个体内逆转录病毒平台, 实施高优先级GOI的表达或shRNA敲低。 就其本质而言,核心C与PPG的其他组件高度互动。项目1、2和 3将进入核心C,它将分析样本与项目的输入,并整合结果之间的 三个项目。核心C将与核心A、B和D进行大量交互,以提供管理支持并识别基因 新的小鼠品系和免疫染色分析的目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

E. John Wherry其他文献

Preferential Loss of Peripheral Non-Naïve CD4+ Lymphocytes in Pediatric Sepsis
  • DOI:
    10.1016/j.jaci.2020.12.010
  • 发表时间:
    2021-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Robert Lindell;E. John Wherry;Scott Weiss;Sarah Henrickson
  • 通讯作者:
    Sarah Henrickson
Tu1897 - Human Norovirus-Specific T Cell Responses
  • DOI:
    10.1016/s0016-5085(17)33394-2
  • 发表时间:
    2017-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Vesselin Tomov;Olesya Palko;Chi W. Lau;Meenakshi Bewtra;E. John Wherry
  • 通讯作者:
    E. John Wherry
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy
针对接受 B 细胞耗竭疗法的多发性硬化症患者,对 COVID-19 疫苗具有持久的 T 细胞免疫力
  • DOI:
    10.1038/s41541-025-01151-8
  • 发表时间:
    2025-05-17
  • 期刊:
  • 影响因子:
    6.500
  • 作者:
    Julia Davis-Porada;Ceren Tozlu;Claudia Aiello;Sokratis A. Apostolidis;Amit Bar-Or;Riley Bove;Diego A. Espinoza;Sugeidy Ferreira Brito;Dina Jacobs;Mihir Kakara;Kaho Onomichi;Adelle Ricci;Joseph J. Sabatino;Elizabeth Walker;E. John Wherry;Lili Zhang;Wen Zhu;Zongqi Xia;Philip De Jager;Sarah Flanagan Wesley;Rebecca Straus Farber;Donna L. Farber
  • 通讯作者:
    Donna L. Farber
CD8sup+/sup T cells in the cancer-immunity cycle
癌症免疫循环中的 CD8 阳性 T 细胞
  • DOI:
    10.1016/j.immuni.2023.09.005
  • 发表时间:
    2023-10-10
  • 期刊:
  • 影响因子:
    26.300
  • 作者:
    Josephine R. Giles;Anna-Maria Globig;Susan M. Kaech;E. John Wherry
  • 通讯作者:
    E. John Wherry
The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8sup+/sup T cells
SWI/SNF 染色质重塑复合物 BAF 和 PBAF 差异调节耗竭 CD8+T 细胞中的表观遗传转变
  • DOI:
    10.1016/j.immuni.2023.05.008
  • 发表时间:
    2023-06-13
  • 期刊:
  • 影响因子:
    26.300
  • 作者:
    Amy E. Baxter;Hua Huang;Josephine R. Giles;Zeyu Chen;Jennifer E. Wu;Sydney Drury;Katherine Dalton;Simone L. Park;Leonel Torres;Brandon W. Simone;Max Klapholz;Shin Foong Ngiow;Elizabeth Freilich;Sasikanth Manne;Victor Alcalde;Viktoriya Ekshyyan;Shelley L. Berger;Junwei Shi;Martha S. Jordan;E. John Wherry
  • 通讯作者:
    E. John Wherry

E. John Wherry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('E. John Wherry', 18)}}的其他基金

Engineering HIV-specific T cells that have improved function and persistence
改造 HIV 特异性 T 细胞,改善其功能和持久性
  • 批准号:
    9891735
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Engineering HIV-specific T cells that have improved function and persistence
改造 HIV 特异性 T 细胞,改善其功能和持久性
  • 批准号:
    10617349
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
Tox 对耗竭 CD8 T 细胞的分化和表观遗传学的时间控制
  • 批准号:
    10685264
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
Tox 对耗竭 CD8 T 细胞的分化和表观遗传学的时间控制
  • 批准号:
    10096485
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Engineering HIV-specific T cells that have improved function and persistence
改造 HIV 特异性 T 细胞,改善其功能和持久性
  • 批准号:
    10450648
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
Tox 对耗竭 CD8 T 细胞的分化和表观遗传学的时间控制
  • 批准号:
    10267763
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
Tox 对耗竭 CD8 T 细胞的分化和表观遗传学的时间控制
  • 批准号:
    10462695
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Engineering HIV-specific T cells that have improved function and persistence
改造 HIV 特异性 T 细胞,改善其功能和持久性
  • 批准号:
    10165494
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Project 3: Genetic and epigenetic basis of resistance to RT and ICB
项目3:RT和ICB抗性的遗传和表观遗传基础
  • 批准号:
    10360425
  • 财政年份:
    2017
  • 资助金额:
    $ 21.07万
  • 项目类别:
Project 3: Genetic and epigenetic basis of resistance to RT and ICB
项目3:RT和ICB抗性的遗传和表观遗传基础
  • 批准号:
    10005192
  • 财政年份:
    2017
  • 资助金额:
    $ 21.07万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 21.07万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 21.07万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 21.07万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 21.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了